Welcome to our searchable resource and literature collection on safer supply and related topics.
Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.
The purpose of this mixed studies systematic review is to describe the state of science on the maternal outcomes and experiences after child custody loss among mothers who use drugs.
This study assessed the relationship between median fentanyl concentration in expected opioid drug checking samples and the death rate due to illicit drug toxicity over time in Vancouver, Canada.
Recently declared an emerging health threat in the U.S., the prevalence of xylazine in overdose deaths increased 5.5-fold between 2019 and 2021.
Safer supply pilot programs provide prescribed doses of pharmaceutical alternatives to individuals accessing the unregulated drug supply and have been implemented to prevent overdose and reduce rel
Our objectives were to curate information about xylazine through social media from people who use drugs (PWUDs).
In early 2021, both Oregon and Washington fully (Oregon) or partially (Washington) decriminalized possession of small amounts of all drugs.
The Safer Bathroom project sought to address long-standing policy and practice gaps by developing a toolkit to improve bathroom overdose prevention and response.
We examined acceptability of and preferences for potential medications for treating methamphetamine use disorder (MUD) among people who use methamphetamine and examined how benefits and drawbacks o
A scoping review was undertaken to examine the impact of methamphetamine use on medications for opioid use disorder [MOUD] retention.
We conducted a qualitative study evaluating one opioid treatment program's experience, including benefits and challenges with implementing a methadone van, to inform future policy and clinical prac
We discuss major domains of xylazine’s harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine’s public health and policy context.
The COVID-19 pandemic led to an unprecedented relaxation of restrictions on take-home doses in opioid agonist treatment (OAT).
Emerging literature suggests that healthcare workers also experience moral injury, particularly in the context of the ongoing COVID-19 pandemic.
Some Rights Reserved Substance Use Health Network and National Safer Supply Community of Practice
